AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion
AbbVie reported Q3 2026 revenue of $17.4B, up 10.3% YoY. GAAP EPS rose to $2.37, while adjusted EPS reached $3.82. Growth was driven by immunology and neuroscience products, though aesthetics revenue declined 1.4%. The company raised 2026 adjusted EPS guidance to $13.95–$13.99 and increased its dividend by 5.2%. AbbVie also completed the acquisition of Apogee Therapeutics and received FDA approvals for Skyrizi and Juvmo.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to drive immediate upside, while the dividend increase adds yield appeal.
Market read
A large‑cap pharma with strong earnings and guidance lift, relevant for healthcare sector positioning.
What to watch
Potential headwinds from upcoming patent expirations and competitive pressures in immunology.
Background
AbbVie’s Q3 release includes revenue growth across immunology and neuroscience, FDA approvals for new indications, and completion of the Apogee Therapeutics acquisition.
Ticker impact
AbbVie reported Q3 revenue up 10.3% YoY, raised 2026 adjusted EPS guidance to $13.95‑$13.99 and announced a 5.2% dividend increase.
upward pressure as investors price in higher earnings outlook and dividend hike
Revenue beat, EPS more than doubled, guidance raise and dividend increase are material new information for a large‑cap pharma.
Market effects
Strengthens outlook for the broader pharma sector as a bellwether beats expectations.
Positive for US healthcare equities in the afternoon session.
May influence global biotech sentiment given AbbVie's size and pipeline.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyAbbVie
US‑listed biopharma company (ticker ABBV).
- companyApogee Therapeutics
Acquired by AbbVie; not separately listed.
